Michael Feher

3.9k total citations
137 papers, 2.5k citations indexed

About

Michael Feher is a scholar working on Endocrinology, Diabetes and Metabolism, Surgery and Molecular Biology. According to data from OpenAlex, Michael Feher has authored 137 papers receiving a total of 2.5k indexed citations (citations by other indexed papers that have themselves been cited), including 69 papers in Endocrinology, Diabetes and Metabolism, 39 papers in Surgery and 26 papers in Molecular Biology. Recurrent topics in Michael Feher's work include Diabetes Treatment and Management (36 papers), Diabetes Management and Research (31 papers) and Lipoproteins and Cardiovascular Health (21 papers). Michael Feher is often cited by papers focused on Diabetes Treatment and Management (36 papers), Diabetes Management and Research (31 papers) and Lipoproteins and Cardiovascular Health (21 papers). Michael Feher collaborates with scholars based in United Kingdom, Italy and Netherlands. Michael Feher's co-authors include Andrew Zambanini, R. S. Elkeles, Roger Newson, Anthony S. Wierzbicki, W. Richmond, Neil Munro, Simon de Lusignan, F B Gibberd, Ian F. Godsland and H Brain and has published in prestigious journals such as SHILAP Revista de lepidopterología, PLoS ONE and The Journal of Clinical Endocrinology & Metabolism.

In The Last Decade

Michael Feher

130 papers receiving 2.4k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Michael Feher United Kingdom 25 1.1k 707 543 410 217 137 2.5k
Roberto Miccoli Italy 31 1.4k 1.3× 828 1.2× 586 1.1× 545 1.3× 246 1.1× 124 3.5k
Cristiane Bauermann Leitão Brazil 30 1.2k 1.1× 933 1.3× 330 0.6× 450 1.1× 195 0.9× 125 2.8k
Yu‐Bae Ahn South Korea 34 1.4k 1.3× 872 1.2× 468 0.9× 601 1.5× 154 0.7× 115 2.9k
Genshi Egusa Japan 27 1.0k 1.0× 973 1.4× 312 0.6× 862 2.1× 219 1.0× 75 2.7k
Anneke C. Muller Kobold Netherlands 37 746 0.7× 641 0.9× 588 1.1× 412 1.0× 149 0.7× 123 3.5k
Dennis Bruemmer United States 15 1.8k 1.7× 639 0.9× 411 0.8× 401 1.0× 108 0.5× 21 2.8k
Jiapu Ge China 8 1.4k 1.3× 382 0.5× 612 1.1× 413 1.0× 185 0.9× 11 2.8k
W. Gatling United Kingdom 21 1.2k 1.1× 349 0.5× 309 0.6× 440 1.1× 234 1.1× 38 1.9k
Xiaohui Guo China 12 1.5k 1.4× 400 0.6× 638 1.2× 392 1.0× 147 0.7× 21 3.0k
Zhigang Zhao China 10 1.3k 1.2× 406 0.6× 642 1.2× 408 1.0× 154 0.7× 29 2.8k

Countries citing papers authored by Michael Feher

Since Specialization
Citations

This map shows the geographic impact of Michael Feher's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Feher with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Feher more than expected).

Fields of papers citing papers by Michael Feher

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael Feher. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Feher. The network helps show where Michael Feher may publish in the future.

Co-authorship network of co-authors of Michael Feher

This figure shows the co-authorship network connecting the top 25 collaborators of Michael Feher. A scholar is included among the top collaborators of Michael Feher based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael Feher. Michael Feher is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Elson, William H., William Hinton, José M Ordóñez-Mena, et al.. (2025). Hepatitis A vaccination coverage in adults with chronic liver disease in primary care in England: a retrospective cohort study. The Lancet Public Health. 10(8). e647–e655.
2.
Hinton, William, Michael Feher, William H. Elson, et al.. (2024). Implementation of chronic kidney disease guidelines for sodium-glucose co-transporter-2 inhibitor use in primary care in the UK: a cross-sectional study. EClinicalMedicine. 68. 102426–102426. 16 indexed citations
3.
Stedman, Mike, George A. Dunn, Martin Gibson, et al.. (2023). Diabetes foot complications and standardized mortality rate in type 2 diabetes. Diabetes Obesity and Metabolism. 25(12). 3662–3670. 10 indexed citations
4.
Lusignan, Simon de, Andrew McGovern, William Hinton, et al.. (2022). Barriers and Facilitators to the Initiation of Injectable Therapies for Type 2 Diabetes Mellitus: A Mixed Methods Study. Diabetes Therapy. 13(10). 1789–1809. 8 indexed citations
5.
6.
Dambha‐Miller, Hajira, William Hinton, Christopher R Wilcox, et al.. (2022). Mortality in COVID-19 among women on hormone replacement therapy: a retrospective cohort study. Family Practice. 39(6). 1049–1055. 16 indexed citations
7.
Dambha‐Miller, Hajira, William Hinton, Christopher R Wilcox, et al.. (2022). Mortality from angiotensin-converting enzyme-inhibitors and angiotensin receptor blockers in people infected with COVID-19: a cohort study of 3.7 million people. Family Practice. 40(2). 330–337. 6 indexed citations
8.
Vlymen, Jeremy van, William Hinton, Gayathri Delanerolle, et al.. (2022). The Effect of the COVID-19 Pandemic on Glycemic Monitoring and Other Processes of Care for Type 2 Diabetes: Protocol for a Retrospective Cohort Study. JMIR Research Protocols. 11(4). e35971–e35971.
9.
Lusignan, Simon de, William Hinton, Samuel Seidu, et al.. (2021). Dashboards to reduce inappropriate prescribing of metformin and aspirin: A quality assurance programme in a primary care sentinel network. Primary care diabetes. 15(6). 1075–1079. 3 indexed citations
10.
Lusignan, Simon de, Richard Hobbs, Harshana Liyanage, et al.. (2020). Improving the Management of Atrial Fibrillation in General Practice: Protocol for a Mixed Methods Study. JMIR Research Protocols. 9(11). e21259–e21259.
11.
Hinton, William, Simon de Lusignan, Rector Arya, et al.. (2019). Metformin is associated with reduced risk of venous thromboembolism in Type 2 diabetes: A national primary care database study. Diabetic Medicine. 36. 19–19. 3 indexed citations
12.
Bain, Stephen C., Michael Feher, Miles Fisher, et al.. (2019). A review of the NG17 recommendations for the use of basal insulin in type 1 diabetes. Diabetic Medicine. 37(2). 219–228. 3 indexed citations
13.
McGovern, Andrew, Michael Feher, Neil Munro, & Simon de Lusignan. (2017). Sodium-Glucose Co-transporter 2 (SGLT2) Inhibitor: Comparing Trial Data and Real-World Use. Diabetes Therapy. 8(2). 365–376. 41 indexed citations
14.
Feher, Michael, et al.. (2014). Anxiety associated with self-monitoring of capillary blood glucose : learning from practice. 11(4). 163–166. 1 indexed citations
15.
McGovern, Andrew, et al.. (2014). Dapagliflozin: Clinical practice compared with pre-registration trial data. The British Journal of Diabetes. 14(4). 138–138. 13 indexed citations
16.
Feher, Michael, et al.. (2013). Persistent hypertriglyceridemia in statin-treated patients with type 2 diabetes mellitus. Diabetes Metabolic Syndrome and Obesity. 6. 11–11. 20 indexed citations
17.
Smith, Martin R. & Michael Feher. (2000). Hormone replacement therapy, cardiovascular risk factors and diabetes. The Journal of the British Menopause Society. 6(3). 94–98. 2 indexed citations
18.
Pickkers, Peter, Michael Schächter, Alun D. Hughes, Michael Feher, & Peter S. Sever. (1996). Thiazide-induced hyperglycaemia: A role for calcium-activated potassium channels?. Diabetologia. 39(7). 861–864. 7 indexed citations
19.
Feher, Michael. (1993). Hypertension in diabetes mellitus. 1 indexed citations
20.
Feher, Michael & D. J. Betteridge. (1989). Lipids, lipoproteins, and coronary heart disease: Implications for antihypertensive therapy. Cardiovascular Drugs and Therapy. 3(S1). 333–340. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Roberto Miccoli Breakdown of academic impact, for papers by Cristiane Bauermann Leitão Breakdown of academic impact, for papers by Yu‐Bae Ahn Breakdown of academic impact, for papers by Genshi Egusa Breakdown of academic impact, for papers by Anneke C. Muller Kobold Breakdown of academic impact, for papers by Dennis Bruemmer Breakdown of academic impact, for papers by Jiapu Ge Breakdown of academic impact, for papers by W. Gatling Breakdown of academic impact, for papers by Xiaohui Guo Breakdown of academic impact, for papers by Zhigang Zhao
Rankless by CCL
2026